Why in news?
Researchers from the University of California, Irvine reported that low dopamine levels in a key brain region directly impair memory formation in Alzheimer’s disease. The study, published in Nature Neuroscience and summarised by science news outlets, suggests that restoring dopamine could improve memory in patients.
Background
Dopamine is a neurotransmitter involved in movement, reward and cognition. Alzheimer’s disease is characterised by progressive memory loss and cognitive decline. Most research has focused on removing amyloid and tau proteins from the brain. However, patients often continue to experience memory deficits even after these proteins are reduced. The new study explores a different mechanism.
Key findings
- Entorhinal cortex involvement. Scientists discovered that dopamine signalling in the entorhinal cortex — a region essential for forming and retrieving memories — was reduced to less than one‑fifth of normal levels in a mouse model of Alzheimer’s.
- Optogenetic stimulation. By using light to activate dopamine‑releasing neurons, researchers restored normal neural activity and improved the animals’ ability to form new memories.
- Drug intervention. Treatment with Levodopa, a drug widely used for Parkinson’s disease, also improved memory formation in the mice, suggesting that existing medications might be repurposed.
- Implications for therapy. Restoring neurotransmitter balance could complement current approaches aimed at removing toxic proteins and may lead to treatments that reverse cognitive decline.
Significance
The study offers a fresh perspective on Alzheimer’s pathology. If low dopamine contributes to memory impairment, therapies that boost or mimic dopamine could help patients. Because drugs like Levodopa are already approved for other disorders, clinical trials may begin sooner. Nonetheless, human studies are needed to confirm whether the findings translate from mice to people.
Source: Medical Xpress
